Related Experiment Video
Updated: Oct 20, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma
Vida Karimnia1, Frank J Slack2, Jonathan P Celli1
1Department of Physics, University of Massachusetts at Boston, Boston, MA 02125, USA.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal of human cancers. Clinical trials of various chemotherapy, radiotherapy, targeted agents and combination strategies have generally failed to provide meaningful improvement in survival for patients with unresectable disease. Photodynamic therapy (PDT) is a photochemistry-based approach that enables selective cell killing using tumor-localizing agents activated by visible or near-infrared light. In recent years, clinical studies have demonstrated the technical feasibility of PDT for patients with locally advanced PDAC while a growing body of preclinical literature has shown that PDT can overcome drug resistance and target problematic and aggressive disease. Emerging evidence also suggests the ability of PDT to target PDAC stroma, which is known to act as both a barrier to drug delivery and a tumor-promoting signaling partner. Here, we review the literature which indicates an emergent role of PDT in clinical management of PDAC, including the potential for combination with other targeted agents and RNA medicine.
Insights
Photodynamic therapy (PDT) shows promise for treating pancreatic cancer (PDAC), a lethal disease. PDT offers a new approach to overcome drug resistance and target tumor stroma, potentially improving patient survival.
Area of Science:
- Oncology
- Photochemistry
- Cancer Therapy
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with limited treatment options for unresectable disease.
- Conventional therapies like chemotherapy and radiotherapy have shown minimal survival benefits.
- Photodynamic therapy (PDT) utilizes light-activated agents for selective tumor cell destruction.
Purpose of the Study:
- To review the emergent role of photodynamic therapy (PDT) in the clinical management of pancreatic ductal adenocarcinoma (PDAC).
- To explore PDT's potential in overcoming drug resistance and targeting the PDAC stroma.
- To discuss PDT's compatibility with combination strategies, including targeted agents and RNA medicine.
Main Methods:
- Literature review of preclinical and clinical studies on PDT for PDAC.
- Analysis of PDT's mechanisms of action, including selective cell killing and stroma targeting.
- Evaluation of emerging evidence for PDT in combination therapies.
Main Results:
- Clinical studies confirm the technical feasibility of PDT for locally advanced PDAC.
- Preclinical data indicate PDT's efficacy in overcoming drug resistance and targeting aggressive disease.
- Emerging evidence suggests PDT can target the PDAC tumor stroma, a barrier to treatment.
Conclusions:
- PDT presents a promising therapeutic strategy for pancreatic ductal adenocarcinoma (PDAC).
- PDT's ability to target tumor stroma and overcome drug resistance warrants further investigation.
- Combination strategies involving PDT, targeted agents, and RNA medicine may enhance treatment outcomes for PDAC.
More Related Videos
11:04An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
Published on: January 13, 2023
06:21Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019